Skip to Content
Cancer Diagnosis Program
Contact NExT
Show menu
Search this site

Welcome to the Cancer Diagnosis Program!

The Cancer Diagnosis Program strives to improve the diagnosis and assessment of cancer by effectively moving new scientific knowledge into clinical practice. This national program stimulates, coordinates and funds resources and research for the development of innovative in vitro diagnostics, novel diagnostic technologies and appropriate human specimens in order to better characterize cancers and allow improved medical decision making and evaluation of response to treatment.

For more information about the Cancer Diagnosis Program and its Branches, please click here.

News and Announcements

10/2024
Registration is now open for the Transformative Microsystem Technologies for Cancer Diagnostics, Monitoring Treatment Response, and Management Workshop, taking place virtually on February 5-6, 2025. View the agenda and register for the workshop on the event website here.
02/2024
Summary and recordings from the March 2024 NCI Workshop on Digital Pathology Imaging (DPI) in Cancer Clinical Trials and Research are now available here.
07/2023
Summary and recordings from the September 2023 NCI Workshop on ctDNA in Cancer Treatment and Clinical Care are now available here.
01/2023
Guidance for investigators interested in P01 Funding for DCTD research areas is now available here.
06/2022
Visit this page to see the schedule of CDP and other DCTD programs presentations at 2022 ASCO.
04/2022
Click here to see a list of presentations by CDP and other DCTD programs at 2022 AACR.
03/2022
CDP’s Dr. Magdalena Thurin participated in ASCO/CAP Immune Checkpoint Inhibitor (ICI) Predictive Factor Virtual Summit in September 2021; slides and recordings are now available here. Exit Disclaimer
11/2021
In September, NCI hosted the FDA/NIH Next Generation Sequencing and Radiomics Workshop: Resource Requirements for Acceleration of Clinical Applications Including Artificial Intelligence.
10/2021
CDP's Dr. Brian Sorg is involved in a cross-agency collaboration with NASA, FDA, NIH, and HHS's BARDA that could lead to unprecedented advancements personalized medicine by extending the life of tissue chips.
09/2021
Dr. Lyndsay Harris, Associate Director of the CDP, commemorates the 50th anniversary of the National Cancer Act with a Staff Highlight in the DCTD newsletter on the evolution of cancer biomarkers, diagnostics, and where research is headed.